21世纪经济报道记者季媛媛 上海报道一家市值蒸发近90%的创新医疗器械企业,一个背负亏损压力的国产医疗器械巨头,正试图在行业周期性调整阶段试图通过一场内部重组寻找新的生机。7月16日,心通医疗-B(02160.HK)发布公告,公司董事会收到公司控股股东微创医疗科学有限公司("微创®",连同其附属公司统称"微创®集团")的不具约束力建议书,内容有关建议策略性重组微创集团的心律管理业务,据此,待与有...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.